Original Article

You have full text access to this OnlineOpen article

Androgen receptors frequently are expressed in breast carcinomas

Potential relevance to new therapeutic strategies

  1. Farid Moinfar M.D.1,‡,*,
  2. Murat Okcu M.D.1,
  3. Oleksiy Tsybrovskyy M.D.1,
  4. Peter Regitnig M.D.1,
  5. Sigurd F. Lax M.D.1,
  6. Wolfgang Weybora M.D.1,
  7. Manfred Ratschek M.D.1,
  8. Fattaneh A. Tavassoli M.D.2,†,
  9. Helmut Denk M.D.1

Article first published online: 25 JUN 2003

DOI: 10.1002/cncr.11532

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 703–711, 15 August 2003

Additional Information

How to Cite

Moinfar, F., Okcu, M., Tsybrovskyy, O., Regitnig, P., Lax, S. F., Weybora, W., Ratschek, M., Tavassoli, F. A. and Denk, H. (2003), Androgen receptors frequently are expressed in breast carcinomas. Cancer, 98: 703–711. doi: 10.1002/cncr.11532

Author Information

  1. 1

    Department of Pathology, School of Medicine, Karl-Franzens University Graz, Graz, Austria

  2. 2

    Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology, Washington, DC

  1. †

    Department of Pathology, Yale University, New Haven, Connecticut

  1. ‡

    Fax: (011) 43 316 384329

*Department of Pathology, Karl-Franzens University Graz, A-8036 Graz, Austria

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 25 JUN 2003
  3. Manuscript Accepted: 17 APR 2003
  4. Manuscript Revised: 30 JAN 2003
  5. Manuscript Received: 11 NOV 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (287K)

REFERENCES

  • 1
    Manni A, Arafah B, Pearson OH. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer. 1980; 46: 2838–2841.
    Direct Link:
  • 2
    Skinner LG, Barnes DM, Ribeiro GG. The clinical value of multiple steroid receptor assays in breast cancer management. Cancer. 1980; 46: 2939–2945.
    Direct Link:
  • 3
    Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977; 37: 4669–4671.
  • 4
    Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979; 44: 671–675.
    Direct Link:
  • 5
    Chevallier B, Heintzmann F, Mosseri V, et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis. Cancer. 1988; 62: 2517–2524.
    Direct Link:
  • 6
    Stanford JL, Szklo M, Brinton LA. Estrogen receptors and breast cancer. Epidemiol Rev. 1986; 8: 42–59.
  • 7
    Wittliff JL. Specific receptors of the steroid hormones in breast cancer. Semin Oncol. 1974; 1: 109–118.
  • 8
    Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer. 1984; 53: 630–643.
    Direct Link:
  • 9
    McGuire WL, Clark GM. Role of progesterone receptors in breast cancer. Semin Oncol. 1985; 12: 12–16.
  • 10
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177–182.
  • 11
    Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995; 35: 283–291.
  • 12
    Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001; 116: 495–503.
  • 13
    Zeillinger R, Kury F, Czerwenka K, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989; 4: 109–114.
  • 14
    Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene. 1992; 7: 1027–1032.
  • 15
    Hubbard AL, Doris CP, Thompson AM, Chetty U, Anderson TJ. Critical determination of the frequency of c-erbB-2 amplification in breast cancer. Br J Cancer. 1994; 70: 434–439.
  • 16
    Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999; 112(1 Suppl 1 ): S53–S67.
  • 17
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719–726.
  • 18
    Persijn JP, Korsten CB, Engelsman E. Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. Br Med J. 1975; 4: 503.
  • 19
    Lippman M, Huff K. A demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay. Cancer. 1976; 38: 868–874.
    Direct Link:
  • 20
    Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer. 1984; 54: 2436–2440.
    Direct Link:
  • 21
    Brys M, Semczuk A, Baranowski W, Jakowicki J, Krajewska WM. Androgen receptor (AR) expression in normal and cancerous human endometrial tissues detected by RT-PCR and immunohistochemistry. Anticancer Res. 2002; 22: 1025–1031.
  • 22
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403–410.
    Direct Link:
  • 23
    Tavassoli FA. Pathology of the breast. Stamford, CT: Appleton & Lange, 1998.
  • 24
    Tavassoli FA. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol. 1998; 11: 140–154.
  • 25
    SPSS. Professional statistics. Version 6.1. Chicago: SPSS Inc., 1993.
  • 26
    SPSS. Categorical principal component analysis (CATPCA). Chicago: SPSS Inc., 1999.
  • 27
    Lippman M, Bolan G, Huff K. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976; 36: 4610–4618.
  • 28
    Zava DT, Landrum B, Horwitz KB, McGuire WL. Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors. Endocrinology. 1979; 104: 1007–1012.
  • 29
    Miller WR, Telford J, Dixon JM, Hawkins RA. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol. 1985; 21: 539–542.
  • 30
    Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res. 1989; 49: 7162–7167.
  • 31
    Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 1997; 193: 753–758.
  • 32
    Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol. 2001; 32: 487–493.
  • 33
    Selim AG, El-Ayat G, Wells CA. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol. 2002; 55: 14–16.
  • 34
    Bundred NJ, Stewart HJ, Shaw DA, Forrest AP, Miller WR. Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer. Eur J Cancer. 1990; 26: 1145–1147.
  • 35
    Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993; 170: 31–35.
    Direct Link:
  • 36
    Smith JA, King RJ. Effects of steroids on growth of an androgen-dependent mouse mammary carcinoma in cell culture. Exp Cell Res. 1972; 73: 351–359.
  • 37
    Luthy IA, Begin D, Labrie F. Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17 beta-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture. Endocrinology. 1988; 123: 1418–1424.
  • 38
    AMA Committee on Research. Androgens and estrogens in the treatment of disseminated mammary carcinoma. J Am Med Assoc. 1960; 172: 1271–1274.
  • 39
    Dilley WG, Leight GS Jr., Silva JS, Ammirata S, Haagensen DE, Wells SA Jr. Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma. J Natl Cancer Inst. 1983; 70: 69–74.
  • 40
    Miller WR, McDonald D, Forrest AP, Shivas AA. Metabolism of androgens by human breast tissue. Lancet. 1973; 1: 912–913.
  • 41
    Nimrod A, Ryan KJ. Aromatization of androgens by human abdominal and breast fat tissue. J Clin Endocrinol Metab. 1975; 40: 367–372.
  • 42
    Brueggemeier RW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat. 2002; 74: 177–185.
  • 43
    Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002; 20: 3317–3327.
  • 44
    Assikis VJ, Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Semin Oncol. 2002; 29 ( 3 Suppl 11 ): 120–128.
View Full Article (HTML) Get PDF (287K)